Last updated on July 2018

Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures


Brief description of study

Fracture healing is a complex physiological process caused by interaction of cellular elements, cytokines and signaling proteins, which results in the formation of new bone. There is for now no universally accepted approach to evaluate the progression of fracture healing. Typically, a fracture is considered as a delayed-union when the bone has not united within a period of time that would be considered adequate for bone healing. Delayed-union suggests that union is slow but will eventually occur without additional surgical or non-surgical intervention, whereas non-union is defined as the cessation of all reparative process of healing. The incidence of impaired healing is estimated to range from 5 to 10% of all long bone fractures, depending on the fracture site, the type and degree of injury, among other factors. Currently the treatment of choice remains bone allograft or autograft. This procedure shows in general good results but requires an invasive surgery of several hours under general anesthesia, followed by a few days of hospitalization. Because of this, major complications have been reported in up to 20-30% of patients. The present Phase 1/2a study aims at demonstrating the safety and efficacy of ALLOB®, a proprietary population of allogeneic osteoblastic cells, in the treatment of delayed-union fractures of long bones. In this study, delayed-union is defined at the time of screening as an absence of healing of minimum 3 months and maximum 7 months (+/- 2 weeks) after the onset of the fracture.

Clinical Study Identifier: NCT02020590

Contact Investigators or Research Sites near you

Start Over

Miguel Forte, MD, PhD

Investigating site BE01
Anderlecht, Belgium

Miguel Forte, MD, PhD

Investigating site BE03
Brussels, Belgium

Miguel Forte, MD, PhD

Investigating site BE08
Brussels, Belgium

Miguel Forte, MD, PhD

Investigating site BE09
Brussels, Belgium

Miguel Forte, MD, PhD

Investigating site BE10
Brussels, Belgium

Miguel Forte, MD, PhD

Investigating site BE02
Charleroi, Belgium

Miguel Forte, MD, PhD

Investigating site BE05
Genk, Belgium

Miguel Forte, MD, PhD

Investigating site DE01
Koln, Germany

Miguel Forte, MD, PhD

Investigating site DE03
Lubeck, Germany

Miguel Forte, MD, PhD

Investigating site DE02
Munich, Germany

Miguel Forte, MD, PhD

Investigating site DE04
Wurzburg, Germany

Miguel Forte, MD, PhD

Investigating site UK01
London, United Kingdom

Miguel Forte, MD, PhD

Investigating site UK02
Norwich, United Kingdom